Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures

NeuroSignals

Volumn 21, Issue 3-4, 2013, Pages 197-212

  Heine, C ^a   Sygnecka, K ^a   Scherf, N ^a,b   Berndt, A ^c   Egerland, U ^c   Hage, T ^c   Franke, H ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Biocrea   (Germany)

Author keywords

Axonal outgrowth; Biocytin; Development; Dopaminergic system; Organotypic slice co culture; Phosphodiesterase; Regeneration; Repair; Tracing; Tyrosine hydroxylase

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; BAY 607550; BIOCYTIN; CYCLIC GMP; DIMETHYL SULFOXIDE; ND 7001; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10; PHOSPHODIESTERASE 2 INHIBITOR; PHOSPHODIESTERASE 2A; PHOSPHODIESTERASE INHIBITOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; BAY 60 7550; NERVE GROWTH FACTOR;

ARTICLE; BRAIN REGION; CELL DENSITY; CELL STRAIN HEK293; COCULTURE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; GENETIC TRANSFECTION; GROWTH ACCELERATION; GROWTH STIMULATION; HUMAN; HUMAN CELL; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; LABELING INDEX; NERVE FIBER GROWTH; NERVE REGENERATION; NEWBORN; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY LABELING; CELL BODY; CONFOCAL LASER MICROSCOPY; CORPUS STRIATUM; EMBRYO; ENZYME ACTIVE SITE; HEK293 CELL LINE; IC50; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; SEQUENCE HOMOLOGY; SLICE CULTURE;

ANIMALS; AXONS; NEURONS; ORGAN CULTURE TECHNIQUES; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; VENTRAL TEGMENTAL AREA;

EID: 84878016741     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000338020     Document Type: Article

References (60)

1. Redgrave P, Rodriguez M, Smith Y, Rodriguez- Oroz MC, Lehericy S, Bergman H, et al: Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci 2010; 11: 760-772.
2. Sesack SR, Carr DB: Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol Behav 2002; 77: 513- 517.
3. Dailly E, Chenu F, Renard CE, Bourin M: Dopamine, depression and antidepressants. Fundam Clin Pharmacol 2004; 18: 601-607.
4. Wise RA: Roles for nigrostriatal - not just mesocorticolimbic - dopamine in reward and addiction. Trends Neurosci 2009; 32: 517-524.
5. Hokfelt T, Johansson O, Fuxe K, Goldstein M, Park D: Immunohistochemical studies on the localization and distribution of monoamine neuron systems in the rat brain. I. Tyrosine hydroxylase in the mes- and diencephalon. Med Biol 1976; 54: 427-453.
6. Fallon JH, Loughlin SE: Substantia nigra; in Paxinos G (ed): The Rat Nervous System. San Diego, Academic Press, 1995, pp 215-237.
7. Lindvall O, Bjorklund A: Cell therapy in Parkinson's disease. Neurotherapeutics 2004; 1: 382-393.
8. Bjorklund A, Dunnett SB: Dopamine neuron systems in the brain: an update. Trends Neurosci 2007; 30: 194-202.
9. Sasaki T, Kotera J, Omori K: Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. J Neurochem 2004; 89: 474-483.
10. Franke H, Schelhorn N, Illes P: Dopaminergic neurons develop axonal projections to their target areas in organotypic co-cultures of the ventral mesencephalon and the striatum/ prefrontal cortex. Neurochem Int 2003; 42: 431-439.
11. Franke H, Illes P: Involvement of P2 receptors in the growth and survival of neurons in the CNS. Pharmacol Ther 2006; 109: 297- 324.
12. Heine C, Wegner A, Grosche J, Allgaier C, Illes P, Franke H: P2 receptor expression in the dopaminergic system of the rat brain during development. Neuroscience 2007; 149: 165-181.
13. Song HJ, Poo MM: Signal transduction underlying growth cone guidance by diffusible factors. Curr Opin Neurobiol 1999; 9: 355- 363.
14. Tojima T, Kobayashi S, Ito E: Dual role of cyclic AMP-dependent protein kinase in neuritogenesis and synaptogenesis during neuronal differentiation. J Neurosci Res 2003; 74: 829-837.
15. Cai D, Shen Y, De Bellard M, Tang S, Filbin MT: Prior exposure to neurotrophins blocks inhibition of axonal regeneration by MAG and myelin via a cAMP-dependent mechanism. Neuron 1999; 22: 89-101.
16. Francis SH, Turko IV, Corbin JD: Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 2001; 65: 1-52.
17. Bender AT, Beavo JA: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488- 520.
18. Conti M, Beavo J: Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76: 481- 511.
19. Rutten K, Prickaerts J, Hendrix M, van der Staay FJ, Sik A, Blokland A: Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol 2007; 558: 107-112.
20. Stephenson DT, Coskran TM, Wilhelms MB, Adamowicz WO, O'Donnell MM, Muravnick KB, et al: Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J Histochem Cytochem 2009; 57: 933-949.
21. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, et al: Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006; 51: 386-396.
22. Chappie T, Humphrey J, Menniti F, Schmidt C: PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. Curr Opin Drug Discov Devel 2009; 12: 458-467.
23. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, et al: Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 2009; 331: 574-590.
24. Nishi A, Snyder GL: Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. J Pharmacol Sci 2010; 114: 6-16.
25. Hofgen N, Stange H, Schindler R, Lankau HJ, Grunwald C, Langen B, et al: Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitors. J Med Chem 2010; 53: 4399-4411.
26. Paglia MJ, Mou H, Cote RH: Regulation of photoreceptor phosphodiesterase (PDE6) by phosphorylation of its inhibitory gamma subunit re-evaluated. J Biol Chem 2002; 277: 5017-5023.
27. Vivas FA, Pestana RC, Ursin B: A new stabilized least-squares imaging condition. J Geophys Eng 2009; 6: 264-268.
28. Rudin LI, Osher S, Fatemi E: Nonlinear total variation based noise removal algorithms. Physica D: Nonlinear Phenomena 1992; 60: 259-268.
29. Gonzalez RC, Woods RE: Digital Image Processing, ed 2. Prentice Hall International, 2001.
30. Otsu N: A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern 1979; 9: 62-66.
31. Gomez-Urquijo SM, Hokfelt T, Ubink R, Lubec G, Herrera-Marschitz M: Neurocircuitries of the basal ganglia studied in organotypic cultures: focus on tyrosine hydroxylase, nitric oxide synthase and neuropeptide immunocytochemistry. Neuroscience 1999; 94: 1133-1151.
32. Polleux F, Morrow T, Ghosh A: Semaphorin 3A is a chemoattractant for cortical apical dendrites. Nature 2000; 404: 567-573.
33. Jaumotte JD, Zigmond MJ: Dopaminergic innervation of forebrain by ventral mesencephalon in organotypic slice co-cultures: effects of GDNF. Brain Res Mol Brain Res 2005; 134: 139-146.
34. Tamariz E, Diaz-Martinez NE, Diaz NF, Garcia-Pena CM, Velasco I, Varela-Echavarria A: Axon responses of embryonic stem cell-derived dopaminergic neurons to semaphorins 3A and 3C. J Neurosci Res 2010; 88: 971-980.
35. Voorn P, Kalsbeek A, Jorritsma-Byham B, Groenewegen HJ: The pre- and postnatal development of the dopaminergic cell groups in the ventral mesencephalon and the dopaminergic innervation of the striatum of the rat. Neuroscience 1988; 25: 857-887.
36. Van Staveren WCG, Steinbusch HWM, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J, et al: mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 2003; 467: 566-580.
37. Smoake JA, Song SY, Cheung WY: Cyclic-, 5 - -nucleotide phosphodiesterase. Distribution and developmental changes of the enzyme and its protein activator in mammalian tissues and cells. Biochim Biophys Acta 1974; 341: 402-411.
38. Davis CW, Kuo JF: Ontogenetic changes in levels of phosphodiesterase for adenosine- :5 - -monophosphate and glucosine 3 - :5 - - monophosphate in the lung, brain and heart from guinea pigs. Biochim Biophys Acta 1976; 444: 554-562.
39. Juilfs DM, Soderling S, Burns F, Beavo JA: Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol 1999; 135: 67-104.
40. Mehats C, Andersen CB, Filopanti M, Jin SLC, Conti M: Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 2002; 13: 29-35.
41. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, et al: Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 1999; 274: 18438-18445.
42. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, et al: Immunohistochemical localization of PDE10A in the rat brain. Brain Res 2003; 985: 113-126.
43. Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, et al: Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 2006; 139: 597-607.
44. Boess FG, Hendrix M, van der Staay F-J, Erb C, Schreiber R, van Staveren W, et al: Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004; 47: 1081-1092.
45. Deng C, Wang D, Bugaj-Gaweda B, De Vivo M: Assays for cyclic nucleotide-specific phosphodiesterases (PDEs) in the central nervous system (PDE1, PDE2, PDE4, and PDE10). Curr Protoc Neurosci 2007;Chapter 7:Unit 7.21.
46. Bos LB: Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 2006; 12: 680- 686.
47. Song H, Ming G, He Z, Lehmann M, Mc- Kerracher L, Tessier-Lavigne M, et al: Conversion of neuronal growth cone responses from repulsion to attraction by cyclic nucleotides. Science 1998; 281: 1515-1518.
48. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, et al: Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008; 325: 681-690.
49. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, et al: Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 2006; 51: 374-385.
50. Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T, et al: Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 2008; 28: 10460-10471.
51. Sotty F, Montezinho LP, Steiniger-Brach B, Nielsen J: Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. J Neurochem 2009; 109: 766-775.
52. Chao MV: Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003; 4: 299-309.
53. Vaudry D, Stork PJS, Lazarovici P, Eiden LE: Signaling pathways for PC12 cell differentiation: making the right connections. Science 2002; 296: 1648-1649.
54. Ng YP, Wu Z, Wise H, Tsim KWK, Wong YH, Ip NY: Differential and synergistic effect of nerve growth factor and cAMP on the regulation of early response genes during neuronal differentiation. Neurosignals 2009; 17: 111-120.
55. Laasberg T, Pihlak A, Neuman T, Paves H, Saarma M: Nerve growth factor increases the cyclic GMP level and activates the cyclic GMP phosphodiesterase in PC12 cells. FEBS Lett 1988; 239: 367-370.
56. Engele J, Bohn MC: The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia. J Neurosci 1991; 11: 3070-3078.
57. Nikkhah G, Odin P, Smits A, Tingstrom A, Othberg A, Brundin P, et al: Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture. Exp Brain Res 1993; 92: 516- 523.
58. Ostergaard K, Jones SA, Hyman C, Zimmer J: Effects of donor age and brain-derived neurotrophic factor on the survival of dopaminergic neurons and axonal growth in postnatal rat nigrostriatal cocultures. Exp Neurol 1996; 142: 340-350.
59. Schatz DS, Kaufmann WA, Saria A, Humpel C: Dopamine neurons in a simple GDNFtreated meso-striatal organotypic co-culture model. Exp Brain Res 1999; 127: 270-278.
60. Thompson LH, Grealish S, Kirik D, Bjorklund A: Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur J Neurosci 2009; 30: 625-638.